Equities Research Analysts' Updated EPS Estimates for April

Equities Research Analysts’ updated eps estimates for Thursday, April 4th: Arbutus Biopharma (NASDAQ:ABUS) had its market outperform rating reaffirmed by analysts at JMP Securities. JMP Securities currently has a $4.00 price target on the stock. Arcellx (NASDAQ:ACLX) had its outperform rating reaffirmed by analysts at Scotiabank. The firm currently has a $82.00 target price on […]

Related Keywords

United States , Blackrock , Nova Scotia , Canada , America , Piper Sandler , Raymond James , Roth Mkm , Radian Group , Telsey Advisory Group , Evolution Petroleum , Mawson Infrastructure Group , Elevance Health , Citigroup Inc , Knights Group , Barclays Plc , Canaccord Genuity Group Inc , Needham Company , Goldman Sachs Group Inc , Intercontinental Exchange , Nasdaq , Morgan Stanley , Cc Group , Cantor Fitzgerald , Unitedhealth Group , Animal Health Group , Montrose Environmental Group , News Ratings For Arbutus Biopharma Co Daily , Term Municipal Advantage Trust , Scotiabank , Royal Bank , Arbutus Biopharma Co , Equities Research Analyst , Oppenheimer Holdings Inc , Micron Technology , Motorpoint Group , Jefferies Financial Group Inc , Jpmorgan Chase Co , Micro Devices , Rock Long Term Municipal Advantage Trust , Goldman Sachs Group , Global Markets , Telsey Advisory , Health Group , Jefferies Financial Group , Products Partners , Cure Medical , Environmental Group , Infrastructure Group , Owl Capital , Gen Pharma , Arbutus Biopharma Co Daily ,